FOP patient groups have announced an extension of their support to the FOP research team in SGC Oxford led by Dr Alex Bullock since 2008. The team, currently comprising two postdoctoral fellows, is working towards developing a treatment for the rare monogenic disease Fibrodysplasia Ossificans Progressiva (FOP), a disorder that causes severely debilitating extraskeletal bone formation and impairs movement.
We are delighted to announce a groundbreaking partnership between The Brain Tumour Charity and the Structural Genomics Consortium (SGC), an international group of academic and industrial researchers with a strong track record in uncovering new drug targets and initiating clinical trials within unusually short timeframes.
An exhibition of work produced by students of the Arts University Bournemouth in collaboration with the SGC
Registration is now open for the Joint Malaria Symposium: “Science and policy shield the vulnerable from malaria”. The symposium will be held on Monday, 20 June 2016, at McGill University in Montreal, Quebec, Canada from 9am-1pm.
After 12 years, SGC’s pharma partners remain committed to the consortium because, they say, they can reproduce its work. CEO Aled Edwards reflects on the lessons he’s learned from working with industry since the consortium’s inception, and he defines eight principles that when applied in combination to a research program can increase the reliability of the program’s output.
Rachel Harding, a researcher at SGC Toronto, appears on Global News discussing her open science experiment. She's welcomed the world to view her research progress in real-time by placing her lab notes online and explaining her results on her blog Lab Scribbles. Rachel hopes that this will help speed up our understanding of Huntington's disease, a devastating neurodegenerative disorder with no cure and the focus of her research.
DiscoverX Corporation, the leading supplier of innovative cell-based assays and services for drug discovery and development, today announced its partnership with the Structural Genomics Consortium (SGC), a public-private organization established in 2003, to develop selective and potent chemical probes for the unexplored human kinome and to promote open sharing of these probes with the scientific community.
University of Toronto researcher Rachel Harding will be the first known biomedical researcher to welcome the world to review her lab notes in real time.
Podcast: Meet our Researchers
This month, we talk to Dr Wen Hwa Lee, Strategic Alliances Manager at the Structural Genomics Consortium (SGC), part of the Nuffield Department of Clinical Medicine, about how the SGC is revolutionising the way we think about drug discovery.